News
| 3 min read
A novel cannabis-based therapy shows promise as a safe, effective non-opioid alternative for chronic low back pain.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 3 min read
Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.
| 7 min read
Men have long lacked reversible contraceptives, but new hormonal and non-hormonal methods in development could finally give them control over family planning.
| 3 min read
A novel eye drop from LENZ Therapeutics represents the first time the FDA has approved aceclidine, a cholinergic agonist, in any drug.
| 3 min read
The kidney structures replicate newborn-level maturity, enabling studies of complex disease features such as fibrosis and drug toxicity.
| 3 min read
From multiomic diagnostics to quantum computing, leading experts share the untapped opportunities that could reshape the future of therapeutics.
| 4 min read
A gene therapy trial halted after a child’s death, a CRISPR test to detect tuberculosis, a new device for antisense therapies, and more led the news this week.
| 2 min read
A new class of small-molecule drugs could represent a therapeutic modality aimed at eliminating disease-causing proteins before they spread in the body.
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 3 min read
The drugmaker expands access to AI-driven discovery, but also positions its technology to become a standard across the sector.
| 3 min read
New research suggests an unexpected role for T cells during a tumor’s evolution from benign to malignant.
